Idera Pharmaceuticals, Inc.
IMMUNE MODULATION WITH TLR9 AGONISTS FOR CANCER TREATMENT
Last updated:
Abstract:
The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
Status:
Application
Type:
Utility
Filling date:
6 Dec 2021
Issue date:
24 Mar 2022